Pristiq
(Desvenlafaxine)ApprovedSmall molecule
Desvenlafaxine is used to treat depression by helping to balance certain chemicals in the brain that affect mood and emotions.[2] Pristiq is currently approved and in use across 10 indications[4].[1]
Pristiq is one of 281 small molecule programs targeting Depressive Disorder. It is currently in Approved.
10
Indications
26
Total Trials
3
Active Trials
280
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Pristiq
PPrism Pharmaceuticals
Approved
Elavil
AstraZenecaPhase 3
Ketalar
Boehringer IngelheimPhase 3
SAGE-217
BiogenPhase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Psilocybin
COMPASS PathwaysPhase 3
SPD489
TakedaPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Seltorexant
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Depression4 trials
Major Depressive Disorder4 trials
Treatment2 trials
Fibromyalgia2 trials
13 more indications
Oral1 trial
Tension-type headache1 trial
Acute Kidney Injury1 trial
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02320240·3,255,526 enrolled
Antidepressants1 trial
Effect of Antidepressants on White Matter Structure
Unknown status·—·Phase 4·NCT01492621·40 enrolled
Opioid1 trial
Desvenlafaxine in Opioid-Dependent Patients
Completed·—·Phase 4·NCT02200406·18 enrolled
Postpartum Depression1 trial
Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine
Completed·—·Phase 3·NCT01527786·25 enrolled
Hot flashes1 trial
Cohort Study1 trial
Regulatory
FDA Approval Timeline[5]
Mar 4, 2013
DESVENLAFAXINE
NDA NDA204150
Jul 10, 2013
KHEDEZLA
NDA NDA204683
Oct 11, 2013
DESVENLAFAXINE
NDA NDA205208
Jan 28, 2014
DESVENLAFAXINE
NDA NDA205583
Aug 20, 2014
PRISTIQ
NDA NDA021992
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Pristiq drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Desvenlafaxine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Norepinephrine Transporter Inhibitor; Serotonin Transporter Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- PPrism Pharmaceuticals
Patent Landscape[6]
Patent Cliff
Jul 5, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8269040Jul 5, 2027